Introducing ProNephro AKI™ (NGAL), the first FDA-cleared biomarker for pediatric acute kidney injury risk assessment. In conjunction with clinical evaluation, ProNephro AKI is designed to help clinicians identify patients aged 3 months through 21 years at risk of developing, or having persistent, moderate-to-severe AKI within 48-72 hours after ICU admission.
Visit booth 5311 to learn about our NGAL reference interval study and ProNephro AKI's data on precision, sensitivity, and interferences.